Zobrazeno 1 - 10
of 900
pro vyhledávání: '"Martin, Reck"'
Autor:
Frank Griesinger, MD, PhD, Wilfried E.E. Eberhardt, MD, PhD, Wolfgang M. Brueckl, MD, PhD, Horst-Dieter Hummel, MD, PhD, Bastian Jaeschke, MD, Jens Kern, MD, Claas Wesseler, MD, Martina Jänicke, PdD, Annette Fleitz, PhD, Stefan Zacharias, PhD, Annette Hipper, PhD, Annika Groth, MD, PhD, Wilko Weichert, MD, PhD, Steffen Dörfel, Volker Petersen, MD, Jan Schröder, MD, Jochen Wilke, MD, Martin Sebastian, MD, Michael Thomas, MD, PhD, Juliana Ababei, Jürgen Alt, Andreas Ammon, Jürgen Anhuf, Ivo Azeh, Stefan Bauer, Dirk Behringer, Winfried Berger, Christiane Bernhardt, Mathias Bertram, Michael Boesche, Sabine Bohnet, Harald-Robert Bruch, Wolfgang Brückl, Ulrike Burkhard-Meier, Petros Christopoulos, Klaus-Ulrich Däßler, Maike de Wit, Tobias Dechow, Reinhard Depenbusch, Lutz Dietze, Markus Dommach, Wilfried Eberhardt, Corinna Elender, Wolfgang Elsel, Till-Oliver Emde, Martin Faehling, Thomas Fietz, Jürgen R. Fischer, Dimitri Flieger, Anke Freidt, Werner Freier, Christian Frenzel, Florian Fuchs, Roswitha Fuchs, Tobias Gaska, Wolfgang Gleiber, Christian Grah, Frank Griesinger, Christian Grohé, Matthias Groschek, Björn Güldenzoph, Andreas Günther, Siegfried Haas, Matthias Hackenthal, Volker Hagen, Lars Hahn, Verena Hannig Carla, Richard Hansen, Hanns-Detlev Harich, Monika Heilmann, Kathrin Heinrich, Christiane Hering-Schubert, Jörg Heßling, Petra Hoffknecht, Patricia Hortig, Gerdt Hübner, Horst-Dieter Hummel, Ulrich Hutzschenreuter, Thomas Illmer, Georg Innig, Bastian Jaeschke, Christian Junghanß, Ulrich Kaiser, Haytham Kamal, Kato Kambartel, Jens Kern, Martin Kimmich, Dorothea Kingreen, Heinz Kirchen, Martine Klausmann, Ortwin Klein, Konrad Kokowski, Wolfgang Körber, Cornelius Kortsik, Dirk Koschel, Benoit Krämer, Beate Krammer-Steiner, Eckart Laack, Christof Lamberti, Rumo David Leistner, Christoph Losem, Andreas Lück, Christoph Maintz, Kerstin Martin, Dirk Medgenberg, Martin Metzenmacher, Christian Meyer zum Büschenfelde, Philipp Meyn, Enno Moorahrend, Annette Müller, Lothar Müller, Michael Neise, Holger Nückel, Arnd Nusch, Tobias Overbeck, Henning Pelz, Volker Petersen, Bettina Peuser, Margarete Plath, Winfried J. Randerath, Jacqueline Rauh, Martin Reck, Dietmar Reichert, Niels Reinmuth, Marcel Reiser, Roland Repp, Daniel Reschke, Achim Rittmeyer, Yolanda Rodemer, Sandra Sackmann, Parvis Sadjadian, Reiner Sandner, Annette Sauer, Harald Schäfer, Christoph Schaudt, Rudolf Schlag, Burkhard Schmidt, Stephan Schmitz, Jan Schröder, Michael Schroeder, Mathias Schulze, Christian Schumann, Wolfgang Schütte, Martin Schwaiblmair, Florian Schwindt Peter, Martin Sebastian, Bernd Seese, Gernot Seipelt, Thomas Sorgenfrei, Johannes Steiff, Heike Steiniger, Tanja Trarbach, Amanda Tufman, Jens Uhlig, Ursula Vehling-Kaiser, Eyck von der Heyde, Ulla von Verschuer, Cornelius Waller, Thomas Wehler, Georg Weißenborn, Florian Weißinger, Martin Wermke, Claas Wesseler, Jörg Wiegand, Stefan Wilhelm, Jochen Wilke, Mark-Oliver Zahn, Matthias Zaiss, Matthias Zeth
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100626- (2024)
Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNS
Externí odkaz:
https://doaj.org/article/193c505adea04fdda590997c6e7e69c0
Autor:
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo dix Junqueira Pinto, Christian Sebastián Fuentes, Giuseppe Lo Russo, Michael Schenker, Jin Seok Ahn, Martin Reck, Zsolt Szijgyarto, Neda Huseinovic, Eleftherios Zografos, Elena Buss, Neda Stjepanovic, Sean O’Donnell, Filippo de Marinis
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients w
Externí odkaz:
https://doaj.org/article/6e906fdccdde435787415eaa66c8249f
Autor:
Karla Rubio, Jason M. Müller, Aditi Mehta, Iris Watermann, Till Olchers, Ina Koch, Sabine Wessels, Marc A. Schneider, Tania Araujo-Ramos, Indrabahadur Singh, Christian Kugler, Mircea Gabriel Stoleriu, Mark Kriegsmann, Martin Eichhorn, Thomas Muley, Olivia M. Merkel, Thomas Braun, Ole Ammerpohl, Martin Reck, Achim Tresch, Guillermo Barreto
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Background Lung cancer (LC) causes more deaths worldwide than any other cancer type. Despite advances in therapeutic strategies, the fatality rate of LC cases remains high (95%) since the majority of patients are diagnosed at late stages whe
Externí odkaz:
https://doaj.org/article/e22a5b91d35748e1ae7ff637df5c9fe0
Autor:
Enriqueta Felip, David P. Carbone, Martin Reck, Luis Paz-Ares, Yong Yuan, Nan Hu, Niels Reinmuth, Xiaoqing Zhang, Thomas John, Ying Cheng, Shun Lu, Manuel Cobo, Michael Schenker, Tudor-Eliade Ciuleanu, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Eduardo Richardet, Hideaki Mizutani, Bogdan Zurawski, Aurelia Alexandru, Javed Mahmood, Tuli De, Irene Santi, John R. Penrod, Adam Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a mi
Externí odkaz:
https://doaj.org/article/c372aee3045841d7bf925f1ae98c8480
Autor:
Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100624- (2024)
Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients wit
Externí odkaz:
https://doaj.org/article/5159d19b07b0438c8a46366db7862e0c
Autor:
Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-21 (2023)
Abstract Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence in most patients. Current treat
Externí odkaz:
https://doaj.org/article/10e1da2e3d234f1e801863a73f93ec88
Autor:
Mustafa Abdo, Yassine Belloum, David Heigener, Lutz Welker, Sönke vonWeihe, Milena Schmidt, Nadine Heuer‐Olewinski, Iris Watermann, Marlen Szewczyk, Jolanthe Kropidlowski, Thais Pereira‐Veiga, Hatice Elmas, Sven Perner, Stefan Steurer, Harriet Wikman, Klaus Pantel, Martin Reck
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 737-746 (2023)
Alternative sources of tumour information need to be explored in patients with non‐small cell lung cancer (NSCLC). Here, we compared programmed cell death ligand 1 (PD‐L1) expression on cytology imprints and circulating tumour cells (CTCs) with P
Externí odkaz:
https://doaj.org/article/5f86dcedcf5f4cf3aad21b856a6d9805
Autor:
Julia Walter, Diego Kauffmann‐Guerrero, Thomas Muley, Martin Reck, Jan Fuge, Andreas Günther, Raphael W. Majeed, Rajkumar Savai, Ina Koch, Julien Dinkel, Christian Schneider, Karsten Senghas, Sonja Kobinger, Farkhad Manapov, Michael Thomas, Kathrin Kahnert, Hauke Winter, Jürgen Behr, Martin Tammemägi, Amanda Tufman
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8880-8896 (2023)
Abstract Introduction Trials of CT‐based screening for lung cancer have shown a mortality advantage for screening in North America and Europe. Before introducing a nationwide lung cancer screening program in Germany, it is important to assess the c
Externí odkaz:
https://doaj.org/article/4671f4b7e0c547e688273a2e674df6ca
Autor:
Aditi Qamra, Hartmut Koeppen, Fabrice Barlesi, Federico Cappuzzo, Martin Reck, Mark A Socinski, Marcus Ballinger, Robert M Jotte, Barzin Nabet, Minu K Srivastava, Soren Muller, Tianshi Lu, Howard West, Habib Hamidi, Assaf Amitai, David S Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a3510600342247d7b4bbe2442738c4b7
Autor:
Enriqueta Felip, Hiroshi Tanaka, Silvia Novello, Hao Xu, Heather Wakelee, Barbara Gitlitz, Martin Reck, Wei Zou, Elizabeth Bennett, Mark McCleland, Caicun Zhou, Satoshi Oizumi, Anna Kryzhanivska, Virginia McNally, Marcus Ballinger, Meghna Das Thakur, Steven L McCune, John Hamm, Minu K Srivastava, Nasser Altorki, Rüdiger Liersch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low,
Externí odkaz:
https://doaj.org/article/cfe63add9cfe46b48a019fc54672b05f